Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
LeasesOther Gross PP&E Adjustments
Ratios

RedHill Biopharma (RDHL) Cost of Revenue: 2013-2023

Historic Cost of Revenue for RedHill Biopharma (RDHL) over the last 8 years, with Jun 2023 value amounting to $806,000.

  • RedHill Biopharma's Cost of Revenue fell 91.04% to $806,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $20.5 million, marking a year-over-year decrease of 53.33%. This contributed to the annual value of $3.2 million for FY2024, which is 7.72% down from last year.
  • RedHill Biopharma's Cost of Revenue amounted to $806,000 in Q2 2023, which was down 50.00% from $1.6 million recorded in Q1 2023.
  • RedHill Biopharma's Cost of Revenue's 5-year high stood at $19.3 million during Q4 2021, with a 5-year trough of $417,000 in Q1 2019.
  • Moreover, its 3-year median value for Cost of Revenue was $9.1 million (2021), whereas its average is $8.5 million.
  • Per our database at Business Quant, RedHill Biopharma's Cost of Revenue soared by 3,238.35% in 2020 and then tumbled by 91.04% in 2023.
  • Quarterly analysis of 5 years shows RedHill Biopharma's Cost of Revenue stood at $788,000 in 2019, then skyrocketed by 1,251.78% to $10.7 million in 2020, then skyrocketed by 81.51% to $19.3 million in 2021, then plummeted by 55.53% to $8.6 million in 2022, then tumbled by 91.04% to $806,000 in 2023.
  • Its Cost of Revenue stands at $806,000 for Q2 2023, versus $1.6 million for Q1 2023 and $8.6 million for Q4 2022.